InvestorsHub Logo
Followers 52
Posts 3345
Boards Moderated 0
Alias Born 10/26/2013

Re: None

Thursday, 04/06/2017 7:35:26 PM

Thursday, April 06, 2017 7:35:26 PM

Post# of 3283
Spectrum Pharma owns ~20% of CASI. Here's a really a pretty good analyst article on CASIs prospect by Zacks Small Cap Research's Grant Zeng dated April 4th.

http://s1.q4cdn.com/460208960/files/News/2017/April-4-2017_CASI_Zeng.pdf

A Zachs PR titled "CASI Exited Fiscal 2016 with a Strong Balance Sheet" came out the same day. Funny how CASI tanked today w everything going good as it looks like if one read the Analyst report. Just goes to show you that until CASI starts making money it's at the mercy of money managers. Anyhows, it talks of when Evomela, Marqibo, and Zevalin will be approved in China as well as what's going on w CASIs drug ENMD-2076 prospects in FLC. Definitely worth reading.